| Expression pattern: |
UP |
| Associated gene: |
IGF2BP2, TRIM25 |
| Associated microRNA: |
- |
| Biological function: |
promotes immune escape by upregulating PD-L1 expression and impeding CD8+ T cell infiltration and killing |
| Molecular mechanism: |
circRHBDD1 binds IGF2BP2 and disrupts TRIM25-IGF2BP2 interaction, inhibiting IGF2BP2 ubiquitination/degradation; stabilized IGF2BP2 enhances PD-L1 mRNA stability via m6A modification |
| Biological pathway or process: |
immune regulation (promotes); ceRNA regulation (inhibits); m6A modification (promotes); mRNA stability (promotes) |
| Detected method: |
Q
H
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; FISH / smFISH; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Survival Analysis; RNA-seq; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; Transfection; CCK8; EdU Staining; Colony Formation Assay; Flow Cytometry（Non-apoptosis/cycle）; IF (Immunofluorescence); In Vivo Animal Model; H&E Staining; MeRIP / MeRIP-seq; Bioinformatics Analysis; Western Blot |
| Clinical significance: |
high circRHBDD1 expression was significantly correlated with poor overall survival and disease-free survival and was an independent prognostic factor for OS and DFS |
| Description: |
circRHBDD1 is up-regulated in gastric cancer and predicts poor prognosis. It promotes immune escape by increasing PD-L1 expression and suppressing CD8+ T cell infiltration/activity. Mechanistically, circRHBDD1 binds IGF2BP2 and interferes with TRIM25-mediated ubiquitination, stabilizing IGF2BP2, which enhances PD-L1 mRNA stability via m6A modification; nanoparticle-delivered si-circRHBDD1 sensitizes tumors to anti-PD-1 therapy in vivo. |
| Confidence score: |
0.8877 |